Conference links May-July 2025 with leronlimab research

|| || |Date|Indication|Study News|Some Papers, Posters, Abstracts|Somes Notes| |May 6, 2025|HIV: Mothers to newborns (leronlimab PLS)|abstract (Diogo Magnani)|5/6/2025 Immunology 2025 (Honolulu): poster, preclinical|poster title: Enhancing Transplacental Delivery of Monoclonal Antibodies Through FcRn Optimization. Diogo Magnani.| |May 14, 2025|(Long-acting: RNA Structural Switch for mRNA and Gene Therapies)|oral abstract (search for Roza Ogurlu)|5/14/2025 ASGCT 28th Annual Meeting (New Orleans): oral abstract, preclinical|abstract title: Engineering an Endoplasmic Reticulum (ER) Stress Responsive RNA Structural Switch for mRNA and Gene Therapies (103). Roza Ogurlu. download link https://www.dropbox.com/scl/fi/bgq4iqocsx8tara9znw2p/AM25-abstracts-FINAL.pdf?rlkey=29uh90elpygnfx9y7kze4kf82&e| |May 15, 2025|Cancer: Metastatic Triple Negative Breast Cancer (mTNBC)|calendar (Richard Pestell)|5/15/2025 ESMO Breast Cancer Congress (Munich): poster, phase 2|  poster title: 369P - Observed survival following treatment with Leronlimab in patients with metastatic Triple-Negative Breast Cancer (mTNBC). Richard Pestell. After the meeting resources (abstracts & posters) https://oncologypro.esmo.org/meeting-resources?meeting_resources_filter%5Bareas%5D%5B%5D=903| |July 4, 2025|Cancer: Colorectal|calendar (Ari Baron)|  7/4/2025 ESMO Gastrointestinal Cancers Congress (Barcelona): poster, phase 2|  poster title: 134eP - Observed Survival Following Treatment With Leronlimab In Patients With Metastatic Colorectal Cancer. Ari Baron. After the meeting resources (abstracts & posters) https://oncologypro.esmo.org/meeting-resources?meeting_resources_filter%5Bareas%5D%5B%5D=918| |July 7, 2025|Cancer: Metastatic Triple Negative Breast Cancer (mTNBC)|Featured speaker (Richard Pestell)|7/7/2025 Cancer Congress 2025 (Vienna): Featured speaker, phase 2|title: The humanized monoclonal ant-CCR5 antibody blocks breast cancer cellular metastasis and enhances cell death induced by DNA-damaging chemotherapy. Richard Pestell. |